Worth reading
61In focus
Scored from 5 of 6 sectionsDirection
Mixed performance
Direction inferred from the company’s description.Scale
-1497
¥ millions (year-on-year change in operating income)Wording
Avoiding a definitive answer
How definitive the wording is.Contents of this document
Financial Results PresentationFirst quarter of the fiscal year ending March 20275 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales9,700 Millions of yen+13.2%
Operating profit-2,103 Millions of yen
Ordinary income-2,084 Millions of yen
Net income¥-1,907 million profit attributable to owners of the parent
Selling, general and administrative expenses9,554 Millions of yen
Gross Profit MarginCost of sales ratio: 23.2%, an improvement of 4.3 percentage points year on year (gross profit margin itself is not stated)
Operating profit margin-21.7%, a deterioration of 14.6 percentage points year on year
Full-year earnings forecast
Net Sales
45,700 Millions of yen
Operating profit
1,100 Millions of yen
Ordinary income
500 Millions of yen
Profit attributable to owners of the parent
200 Millions of yen
Progress against full-year forecast 通期の予想に対して、いまどこまで進んだかの割合です。
Net Sales21.2%
Cost of sales21.2%
Gross profit21.2%
Selling, general and administrative expenses28.1%
Selling, general and administrative expenses25.2%
Research and development costs30.4%
Revenue breakdownGROWJECT 21.4%, IZCARGO 24.1%, TEMCELL 26.7%, treatment for renal anemia 19.9%, epoetin alfa 12.5%, darbepoetin 24.6%, agalsidase beta 12.3%, total pharmaceuticals 21.6%, contract payments 18.1%
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
GROWJECT fell short of plan. The number of IZCARGO cases increased ahead of plan, while TEMCELL HS Injection performed steadily against plan. Research and development expenses exceeded the plan.Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
- Contract paymentsChange in amount1,367
- Other net salesChange in amount850
- Total pharmaceuticalsChange in amount-1,086
- Research and development costsChange in amount2,540
- Selling, general and administrative expensesChange in amount195
New initiatives
- Preparation for the domestic marketing authorization application for Givinostat within 2026
- Conducting an additional clinical trial of Givinostat in Japanese patients
- Expanding IZCARGO into the United Arab Emirates and the MENA region
- Commencement of a global natural history study for JR-471
Key KPIsA metric the company considers important as a management benchmark.
- Number of IZCARGO treatment cases112 Example
- Cumulative number of IZCARGO treatment cases119 Example
- GROWJECT domestic growth hormone market share37.9 %Year on year against the same period last yearThe year-earlier figure is included in the quarterly trend data in the materials
- Number of ambulatory DMD patients aged 6 or older in Japan1,100 people
Market Size / Share
Domestic growth hormone market share: 31.0% in the private-practice market, 43.7% in the hospital market, and 25.3% in the pharmacy market. GROWJECT's share was 37.9% as of June 2026 (FY2026). The materials state that Japan has more than 1,000 ambulatory DMD patients aged 6 or older.| Item | Details |
|---|---|
| Document type | Financial Results Presentation |
| Fiscal Period Covered | First quarter of the fiscal year ending March 2027 |
| Net Sales | 9,700 Millions of yen (YoY +13.2%) |
| Operating profit | -2,103 Millions of yen |
| Ordinary income | -2,084 Millions of yen |
| Net income | ¥-1,907 million (profit attributable to owners of the parent) |
| Gross Profit Margin | Cost of sales ratio: 23.2%, an improvement of 4.3 percentage points year on year (gross profit margin itself is not stated) |
| Operating profit margin | -21.7%, a deterioration of 14.6 percentage points year on year |
| Selling, general and administrative expenses | 9,554 Millions of yen |
| Full-year earnings forecast | Net Sales 45,700 Millions of yen / Operating profit 1,100 Millions of yen / Ordinary income 500 Millions of yen / Profit attributable to owners of the parent 200 Millions of yen |
| Progress against full-year forecast | Net Sales 21.2% / Cost of sales 21.2% / Gross profit 21.2% / Selling, general and administrative expenses 28.1% / Selling, general and administrative expenses 25.2% / Research and development costs 30.4% / Revenue breakdown GROWJECT 21.4%, IZCARGO 24.1%, TEMCELL 26.7%, treatment for renal anemia 19.9%, epoetin alfa 12.5%, darbepoetin 24.6%, agalsidase beta 12.3%, total pharmaceuticals 21.6%, contract payments 18.1% |
| Self-assessment against the plan | GROWJECT fell short of plan. The number of IZCARGO cases increased ahead of plan, while TEMCELL HS Injection performed steadily against plan. Research and development expenses exceeded the plan. |
| Breakdown of Factors Affecting the Change | Factors Contract payments / Change in amount 1,367 Millions of yen, Factors Other net sales / Change in amount 850 Millions of yen, Factors Total pharmaceuticals / Change in amount -1,086 Millions of yen, Factors Research and development costs / Change in amount 2,540 Millions of yen, Factors Selling, general and administrative expenses / Change in amount 195 Millions of yen |
| Key KPIs | Indicator name Number of IZCARGO treatment cases / Value 112 Example / Year on year against the same period last year Not disclosed, Indicator name Cumulative number of IZCARGO treatment cases / Value 119 Example / Year on year against the same period last year Not disclosed, Indicator name GROWJECT domestic growth hormone market share / Value 37.9 % / Year on year against the same period last year The year-earlier figure is included in the quarterly trend data in the materials, Indicator name Number of ambulatory DMD patients aged 6 or older in Japan / Value 1,100 people / Year on year against the same period last year Not disclosed |
| Market Size / Share | Domestic growth hormone market share: 31.0% in the private-practice market, 43.7% in the hospital market, and 25.3% in the pharmacy market. GROWJECT's share was 37.9% as of June 2026 (FY2026). The materials state that Japan has more than 1,000 ambulatory DMD patients aged 6 or older. |
| New initiatives | Preparation for the domestic marketing authorization application for Givinostat within 2026, Conducting an additional clinical trial of Givinostat in Japanese patients, Expanding IZCARGO into the United Arab Emirates and the MENA region, Commencement of a global natural history study for JR-471 |
Items this document does not state (15)
Results for the three months of the current quarterSegment resultsUnit price and quantity metricsNumber of stores and locationsNumber of employeesAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The increase in net sales was mainly due to higher upfront contract payments. Research and development expenses increased year on year and exceeded the plan because some global clinical trial costs were concentrated in the current period and CRO-related expenses increased.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.